 |
 Video: What is a Stock Split?
|
|
|
| Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The INTERCEPT Blood System, which is based on Co.'s technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Co.'s INTERCEPT Blood System is intented for use with blood components including platelets, plasma and red blood cells. Co. has received U.S. Food and Drug Administration approval for the INTERCEPT Blood System for Cryoprecipitation, which uses Co.'s plasma system to produce INTERCEPT Fibrinogen Complex for the treatment and control of bleeding. According to our Cerus stock split history records, Cerus has had 0 splits. | |
|
Cerus (CERS) has 0 splits in our Cerus stock split history database.
Looking at the Cerus stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cerus shares, starting with a $10,000 purchase of CERS, presented on a split-history-adjusted basis factoring in the complete Cerus stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/28/2014 |
|
| End date: |
04/24/2024 |
|
| Start price/share: |
$4.43 |
|
| End price/share: |
$1.66 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-62.53% |
|
| Average Annual Total Return: |
-9.35% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$3,747.96 |
|
| Years: |
10.00 |
|
|
|
|
|
